History of Formation
Affitech was established in 1997 by a group of Norwegian and German scientists on the basis of the acquisition of the worldwide exclusive rights from German Cancer Center, Heidelberg, Germany of “Breitling “ IP which covered phagemid display of human antibodies.
In May 2009, Affitech AS merged with Pharmexa A/S to form Affitech A/S resulting in the company now being listed on the Nasdaq OMX exchange.
Therapeutic Antibodies
Affitech A/S is one of only a limitied number of independent companies with a strong position in high throughput screen- ing of antibody libraries. With its proprietary technologies, Affitech A/S is developing fully human monoclonal antibody drugs of two types:
- Antibodies directed against molecular targets known to play a role in diseases but not currently addressed by existing drugs, and
- New and improved versions of marketed antibody...